AI-generated from publicly available materials.SimBioSys has received FDA clearance for TumorSight Risk, an innovative AI-based tool designed to assess the risk of breast cancer recurrence using MRI data.
This platform leverages routine breast MRI, pathology, and clinical data to generate personalized prognoses for patients at five and ten years. It specifically aids oncologists in treatment planning for hormone receptor-positive (HR+), HER2-negative Stage I–IIIA breast cancer, which constitutes approximately 75% of breast cancer cases in the U.S. The integration of Nvidia technology enhances the platform's ability to analyze spatial and biological data, offering a more nuanced understanding of recurrence risk.
The FDA clearance is backed by a comprehensive validation study involving over 2,100 patients from leading institutions like Mayo Clinic and Stanford Medicine. Findings indicate that TumorSight Risk effectively stratifies patients by their likelihood of recurrence, with high-risk patients facing a significantly greater risk compared to those classified as low risk. This tool also provides results much faster than traditional methods, with assessments available in as little as one hour, thereby enabling quicker clinical decision-making.
As healthcare increasingly shifts towards personalized medicine, TumorSight Risk represents a critical advancement in breast cancer care. By utilizing existing imaging data, it offers timely insights that can empower clinicians and patients to make informed treatment choices while considering factors like side effects and quality of life.